Strengthen The Impact Of Statin Therapy On Inflammatory Factors And Prognosis Of Patients With Acute Coronary Syndrome

Background and Objective: Statins are able to decrease levers of lipid, reduce the incidence of cardiovascular evidence and improve clinic prognosis in patients with ACS. Studies in recent years show that statins have effects of inhibiting inflammatory response without a decreasing lever of LDL-C and could effect in a short time. But there is no unified dosage by now. Fearing the the adverse reaction of statins, domestic docters prefer to a lower dosage of 10～20 mg/d compare with docters abroad who often use 40～80 mg/d. The objective of this article is to investigate the effect and safety of early intensive statin therapy in patients with ACS through observing the chang of inflammatory factors (hs-CRP,SAA,MMP–9,Fib)and blood lipid(TC, TG ,LDL-C, HDL-C), as well as the differences between two groups on incidence of cardiovascular evidence and the adverse reaction.Method: (1)70 patients with ACS were randomly divided into two groups: groupA and group B. (2)GroupA contained 35 patients taking with 10 mg/d atorvastatin before sleeping besides routine treatments, group B contained 35 patients taking with 40mg/d atorvastatin before sleeping besides routine treatments. All patients were recommended to insist to use atorvastatin when discharged. (3)Before and after one week treatment, the plasma levels of inflammatory factors (hs-CRP,SAA,MMP–9,Fib) and blood lipid(TC, TG ,LDL-C, HDL-C) were detected. (4)All the patients were followed up for 60 days, the incidence of cardiovascular evidence and the adverse reaction of drug were detected. Result: (1)Blood lipid levels have no significant difference in the two groups after treatment with atorvastatin for one week(P>0. 05). ( 2 ) Except Fib, the inflammatory factors of hs-CRP,SAA,MMP–9 all decreased significantly in group A after treatment with atorvastatin for one week(P<0.05), all the four inflammatory factors(hs-CRP,SAA,MMP–9,Fib) decreased significantly in group B, and the changes were more significant in group B than in group A (P<0.05). (3)Compared with groupA,the incidence of cardiovascular evidence in group B were less than that in group A markedly (P<0.05 ). No severe adverse effects were found in two groups(P>0. 05).Conclusion: Early intensive statin therapy could reduce the levels of inflammatory factors, inhibit the inflammatory response, promote the stabilization of atherosclerotic plaque, reduce the incidence of cardiovascular evidence and significantly improve prognosis in patients with ACS. The higher dose, the more benefit. Early intensive statin therapy have good effect and safety in patients with ACS .